Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 35.58% is in line with its 5-year average of 37.03%, near the low end of its 5-year range (19.18%–80.92%).
3.17% below its 12-month average of 36.74%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 30.07%.
GROSS MARGIN
35.58%
GROSS MARGIN AVG TTM
36.74%
GROSS MARGIN AVG 3Y
37.39%
GROSS MARGIN AVG 5Y
37.03%
GROSS MARGIN AVG 10Y
51.24%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-3.17%
CURRENT VS 3Y AVG
-4.85%
CURRENT VS 5Y AVG
-3.91%
CURRENT VS 10Y AVG
-30.56%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.82%
median of 729 covered companies
CURRENT VS SECTOR MEDIAN
-12.84%
vs the sector median at left
Fulgent Genetics, Inc.
Market Cap
$593.40M
Gross Margin
35.58%
TTM Avg
36.74%
3Y Avg
37.39%
5Y Avg
37.03%
Market Cap
$587.91M
Gross Margin
73.65%
TTM Avg
72.81%
3Y Avg
73.64%
5Y Avg
74.48%
Market Cap
$600.01M
Gross Margin
99.76%
TTM Avg
98.92%
3Y Avg
99.03%
5Y Avg
96.38%
Market Cap
$606.73M
Gross Margin
54.62%
TTM Avg
54.27%
3Y Avg
52.72%
5Y Avg
52.86%
Market Cap
$574.01M
Gross Margin
67.04%
TTM Avg
65.22%
3Y Avg
62.15%
5Y Avg
65.14%
Market Cap
$568.20M
Gross Margin
98.63%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fulgent Genetics, Inc. (FLGT) | $593.40M | 35.58% | 36.74% | 37.39% | 37.03% |
| OrthoPediatrics Corp. (KIDS)vs › | $587.91M | 73.65% | 72.81% | 73.64% | 74.48% |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $600.01M | 99.76% | 98.92% | 99.03% | 96.38% |
| AngioDynamics, Inc. (ANGO)vs › | $606.73M | 54.62% | 54.27% | 52.72% | 52.86% |
| Aquestive Therapeutics, Inc. (AQST)vs › | $574.01M | 67.04% | 65.22% | 62.15% | 65.14% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $568.20M | 98.63% | 100.00% | 100.00% | 100.00% |
| CorMedix Inc. (CRMD)vs › | $566.38M | 82.78% | 90.56% | 68.85% | 51.96% |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| Climb Bio, Inc. (CLYM)vs › | $633.90M | 0.00% | 0.00% | 0.00% | 0.00% |
| Prime Medicine, Inc. (PRME)vs › | $633.97M | -58.05% | 20.98% | 10.49% | 14.13% |
Gross Margin
35.6%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 30.07% |
| 2026-03-31 | 30.21% |
| 2025-12-31 | 39.10% |
| 2025-09-30 | 42.24% |
| 2025-06-30 | 42.10% |
| 2025-03-31 | 38.59% |
| 2024-12-31 | 41.79% |
| 2024-09-30 | 37.32% |
| 2024-06-30 | 37.30% |
| 2024-03-31 | 34.28% |
| 2023-12-31 | 35.78% |
| 2023-09-30 | 47.05% |
| 2023-06-30 | 30.32% |
| 2023-03-31 | 28.43% |
| 2022-12-31 | 19.18% |
| 2022-09-30 | 43.63% |
| 2022-06-30 | 52.08% |
| 2022-03-31 | 75.73% |
| 2021-12-31 | 75.31% |
| 2021-09-30 | 80.92% |
| 2021-06-30 | 76.66% |
| 2021-03-31 | 79.39% |
| 2020-12-31 | 82.45% |
| 2020-09-30 | 74.18% |
| 2020-06-30 | 55.30% |
| 2020-03-31 | 47.67% |
| 2019-12-31 | 56.67% |
| 2019-09-30 | 62.45% |
| 2019-06-30 | 57.03% |
| 2019-03-31 | 44.73% |
| 2018-12-31 | 51.33% |
| 2018-09-30 | 53.56% |
| 2018-06-30 | 52.89% |
| 2018-03-31 | 40.43% |
| 2017-12-31 | 40.55% |
| 2017-09-30 | 49.63% |
| 2017-06-30 | 59.50% |
| 2017-03-31 | 64.96% |
| 2016-12-31 | 68.18% |
| 2016-09-30 | 57.23% |
| 2016-06-30 | 64.47% |
| 2016-03-31 | 62.09% |
| 2015-12-31 | 6.03% |
| 2015-09-30 | 68.40% |
| 2015-06-30 | 64.60% |
| 2015-03-31 | 58.88% |
